Confronting the challenges of discovery of novel antibacterial agents  by Singh, Sheo B.
Bioorganic & Medicinal Chemistry Letters 24 (2014) 3683–3689Contents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry Letters
journal homepage: www.elsevier .com/ locate/bmclBMCL DigestConfronting the challenges of discovery of novel antibacterial agentshttp://dx.doi.org/10.1016/j.bmcl.2014.06.053
0960-894X/ 2014 The Author. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
⇑ Tel.: +1 908 9305757.
E-mail address: sheo.singh.215@gmail.comSheo B. Singh ⇑
SBS Pharma Consulting LLC, Edison, NJ 08820, United States
a r t i c l e i n f oArticle history:
Received 28 May 2014
Revised 16 June 2014
Accepted 18 June 2014
Available online 26 June 2014
Keywords:
Antibacterial
Antimicrobial
Topoisomerase II
Phenotypic screening
Discovery strategya b s t r a c t
Bacterial resistance is inevitable and is a growing concern. It can be addressed only by discovery and
development of new agents. However the discovery and development of new antibacterial agents are
at an all time low. This article broadly examines the historical as well as current status of antibacterial
discovery and provides some perspective as how to address some of the challenges.
 2014 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Bacterial infections and the ﬁght against them have been a
focus of mankind since the dawn of time with application of inter-
ventions including mercury salts and herbs. The earliest known
chemotherapeutic antibacterial discovery began in the 20th cen-
tury by screening of compounds from the dye industry leading to
discovery of salvarsan (arsenic derivative of hydroxy aniline,
1910) and the sulfa drugs (1930’s).1 With understanding of the
mechanism of action of sulfa drugs as inhibitors of folate pathway,
targeted screening and lead optimization of the pyrimidine class of
compounds led to discovery and development of trimethoprim
(early 1960’s). However, the true revolution of the antibacterial
discovery did not begin until the discovery of penicillin in 1928
from Penicillium notatum by Sir Alexander Fleming followed by
puriﬁcation, production and clinical treatment in 1940s. This dis-
covery led to a revolution of not only antibacterial discovery but
also the ﬁeld of microbial natural products. Empirical screening
of microbial natural product fermentation broths led to the discov-
ery of the antibacterial natural products in next 20 years (1940–
1962) designated as ‘Golden-Age’ of antibacterial discovery.1,2
Microbial derived antibiotics (b-lactams, aminoglycosides, tet-
racyclines, macrolides, glycopeptides, streptogramins) and
synthetic quinolones discovered during Golden Age served as
drugs or chemical platforms for drug leads for medicinal chemists.
For the next ﬁve to seven decades, optimization of these leads pro-
duced new antibiotics with incrementally improved potency and
properties.3 Improved chemistry, target identiﬁcation and avail-
ability of ligand-bound 3D structure, and increased understandingof resistance mechanisms led to the discovery and development of
as many as six generations of antibiotics of most important clas-
ses.3 Convergent total synthesis of tetracyclines by Myers and
coworkers is the most notable development of new chemistry pub-
lished in a long time.4,5 The new chemistry allowed for the efﬁcient
design of tetracycline analogs not possible before, leading to new
classes of structures including pentacyclines.4,5 While iterative
modiﬁcations to old classes of chemical leads produced new anti-
biotics with improved potency, drug properties, and resistance
proﬁles this process is not limitless and may have run its course.
Despite these challenges, a limited number of compounds from
the established classes of antibiotics are in various stages of
development.6
While the antibacterial ﬁeld is grappling with these challenges,
bacterial resistance continues to grow to all antibiotics regardless
of class and mechanism. Some classes and mechanisms are more
prone to resistance selection than other classes. Bacterial resis-
tance is inevitable. It is not if but when it will occur. Therefore,
to combat resistance, new antibiotics with new mechanisms or
new classes of compounds that bind to new binding sites of the
established targets are needed.
After a signiﬁcant innovation gap3 post ‘Golden Age’ linezolid, a
new synthetic oxazolidinone class of Gram-positive antibiotic was
approved by the FDA in 2000.1 Since then a few other new classes
of Gram-positive antibiotics (daptomycin-2003, retapamutilin-
2007, ﬁdaxomicin-2011) were approved for clinical use.1 Empirical
screening was used to discover these classes of compounds in
1980’s or before.1
So what happened during the last ﬁve decades since the ‘Golden
Age’ of antibiotic discovery that led to discovery void1 of novel
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cency, application of wrong discovery strategies (apparently pru-
dent at the time), de-emphasis of natural products, not enough
emphasis or resources for antibiotic research and development?
Arguably, it is a result of the combination of all the factors
described above. First, after a great success during the Golden
Age of antibiotic discovery, it was assumed that the antibiotic clas-
ses already discovered would be sufﬁcient for the treatment of bac-
terial infections and it was not sufﬁciently appreciated that
bacterial resistance was inevitable under the selective pressure of
antibiotics. Penicillin resistance was known at the time and there-
fore it was not a surprise. This oversight clearly led to compla-
cency, likely poor funding and lack of innovation, until it was
recognized otherwise.
All antibiotics during the Golden Age were discovered by empir-
ical screening using inhibition-of-growth assays. Mechanism of
action was determined much later, sometimes many decades
later.1 The advent of molecular biology, expression and production
of enzymes and receptors made large-scale in vitro enzyme and
receptor based screening routine. This turned out to be highly suc-
cessful approach for chemical lead ﬁnding against a variety of
mammalian targets followed by optimization leading to drugs.
Unfortunately this approach of in vitro cell free screening was
utterly unsuccessful for bacterial targets as reported by GSK in
2007.7 At the time, in comparison to traditional empiric screening,
the in vitro MOA based cell-free approach was very attractive due
to its ‘obvious’ rationality. With that in mind, it is likely that most
of the companies applied similar cell-free screening approaches for
the discovery of antibacterial agents without much success at the
end. Historically, natural products have been a most proliﬁc source
for providing novel antibiotics. However, in the intervening period
most of the companies terminated or reduced their efforts on
screening of natural products due to various reasons not least
due to repeated rediscovery of known compounds. After spending
huge resources for screening without ﬁnding bona ﬁde tractable
leads for chemical optimization to new drugs resulted in tremen-
dous frustration. This led to de-prioritization of the antibacterial
programs in many Pharmaceutical Companies.
The lack of success of the discovery of a good chemical lead for
building a medicinal chemistry program for discovery and devel-
opment of novel antibacterial agents with a novel mechanism of
action could be attributed to two main factors. First and perhaps
most critical is the lack of novel chemical diversity of antibacterial
screening libraries and de-emphasis of natural products, and the
second, the screening approach.
Chemical diversity, and lack thereof, for drug discovery space is
a topic for much debate. Within the conﬁnes of chemical diversity
the antibacterial agents appear to occupy unique property space
compared to other drugs as demonstrated by O’Shea and Moser8
from the analysis of the CMC database. These ﬁndings show that
antibacterial agents: are signiﬁcantly more polar (Gram-negative
agents are much more polar, logD7.4 negative 2.8, than Gram-posi-
tive agents, logD7.4 negative 0.2 vs average CMC data set logD7.4
positive 1.6), do not obey Lipinski rule of ﬁve for oral bioavailabil-
ity (some orally active drugs do obey these rules), display wide
molecular weight (102–1449) ranges (MW: average CMC data set
338 Da, average Gram-positive antibacterial 813 Da and average
Gram-negative antibacterial 414 Da).1 Most of the corporate chem-
ical collections and screening libraries were designed and built up
with oral bioavailability and human targets in mind, leading to
compounds that are much more lipophilic and unlikely to ﬁll the
property and diversity space suitable for antibacterials.9
Failure of the cell free screening approach (wet lab and virtual)
of the bacterial targets is generally due to lack of cellular activity
and lack of understanding of the characteristics required to endow
molecules with cellular entry properties. Unlike mammalian cells,bacterial cells are protected by cell wall (Gram-positive) and by an
outer-membrane in addition to cell wall (Gram-negative). Most of
the bacterial targets with the exception of cell wall/outer mem-
brane targets are intracellular. Therefore, in order to engage with
their biological targets, compounds have to cross these strong pro-
tective barriers often with opposite physical properties.1 Bacteria
do express and use active transports to transport nutrients.
Fortunately, sometimes these active transporters also help trans-
port some of the drugs to periplasm and cytosol. Unfortunately
transporters have not been exploited for drug entry with the
exception of iron transporters (vide infra) perhaps due to lack of
clear understanding of the structure and function of these trans-
porters and also due to the rapid loss of the transporters, leading
to resistance. Transporters often do play a role in transporting nat-
ural product antibiotics and show exclusive selectivity for some
compounds and not for others even within the same class of anti-
biotics. Unfortunately, even if the drugs pass the membrane entry
barrier efﬂux pumps expressed in bacteria, pump them out from
periplasm/cytosol.
Improvement of potency of a chemical lead against an enzyme
target by standard medicinal chemistry approaches, with or with-
out structural information, can be achieved rapidly (e.g., LpxC, vide
infra). However they may fail to kill bacteria because of their fail-
ure to reach the intracellular target (e.g., certain LpxC inhibitors,
vide infra). While some structure-function knowledge exists on
efﬂux pumps, not much is known on cell permeability other than
highly acidic compounds are not as permeable as neutral, zwitter-
ionic, and basic compounds. Balancing of permeability and efﬂux,
the two yin–yang phenomenon, is critical for designing successful
antibiotics. If balancing the target activity, cell penetration and
efﬂux were not challenging enough, their diversity and differential
expression in different bacterial species make the discovery and
development of broad-spectrum antibiotics even more challeng-
ing. Therefore lead optimization of a broad-spectrum antibacterial
program is akin to running a dozen single-target mammalian pro-
grams simultaneously. This is likely one of the reasons for the fail-
ure of the programs originating from cell-free screening efforts
even after good tractable enzyme inhibitors were discovered.
Despite these challenges empirical screening has allowed for the
discovery of many great broad-spectrum antibiotics in the past.
Detailed understanding of cell penetration and efﬂux can make this
ﬁeld wide open for new inventions.
Until resolution of the entry barrier, phenotypic assays repre-
sent the best approach for screening for antibacterial leads. A good
target-based phenotypic screen can help eliminate/reduce the
unwanted detergent-like or poisonous hits. This approach could
focus the lead optimization resources to cell active leads. A few
examples of target based whole cell phenotypic assays that have
been applied for the discovery of new leads are: antisense assays10
(e.g., platensimycin/platencin11,12 and kibdelomycin13), and Wall
Teichoic Acid (WTA) pathway assay.14 Various other target based
whole cell based assays have been reviewed.1,15,16 However, para-
mount to the success of the antibacterial discovery is a structurally
diverse screening library covering antibacterial property space.
Without diverse antibacterial chemical libraries with requisite
antibacterial drug properties no screening method would produce
the desired outcome.
There are approximately 265–350 genetically validated anti-
bacterial targets. Of these about 60% are broad-spectrum targets.17
Astonishingly, no more than 20 of these are targeted by currently
marketed drugs2 and thus provide tremendous opportunity for
the discovery and development of new agents with novel mode
of action without cross-resistance, particularly multi-target mech-
anisms (chemical leads that interact with more than one biological
target). With this kind of analysis and information in hand, the
time is ripe for focusing resources and applying scientiﬁc acumen
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ern chemistry approaches including DOS, BIOS and natural prod-
ucts. This would revitalize lead generation that could be
converted into novel antibacterial drugs with new mode of action
or new mode of binding to existing targets and low potential for
cross-resistance. Meanwhile a narrow range of activity has contin-
ued towards new discoveries. A few vignettes of recent antibacte-
rial drug discovery and development programs have been
summarized here. Discovery of recent natural product leads was
recently described in a BMCL digest article18 and is not covered
here.
Inhibitors of topoisomerases II. A clear pattern emerges upon
careful examination of well-established antibacterial lead/target
pairs. Targets that are highly privileged and bind to only a very
speciﬁc compound classes (e.g., D-ala-D-ala? vancomycin and
PBP? b-lactams)2,19 and targets with promiscuous binding sites
(e.g., ribosome and DNA topoisomerases II). The target promiscuity
provides opportunity to discover novel classes of inhibitors that
bind to a different binding site than targeted by existing clinical
agents and thus avoiding cross-resistance. A wide range of struc-
tural classes/drugs target ribosome, from low MW (e.g., linezolid)
and large MW (e.g., thiostrepton) and structures in between
including chloramphenicol, clindamycin, aminoglycosides (e.g.,
streptomycin), macrolides (e.g., erythromycin, tylosin), streptogra-
mins, and tetracyclines.20
While natural products dominate binding to ribosomal targets
(oxazolidinone is exception), synthetic compounds dominate bind-
ing to bacterial DNA topoisomerases II (gyrase and topoisomerase
IV), which is a target for quinolones and novobiocin (1) and is clini-
cally validated. Signiﬁcant efforts have been made to understand
mechanism of action of the gyrase and topo IV, including solution
of multiple inhibitor bound X-ray crystal structures. While the
mechanism of enzyme inhibition is complex, availability of many
crystal structures made it possible to apply structure based drug
design principles to advance certain screening cell active leads.
The topoisomerase II is an enzyme complex comprising four sub-
units: GyrA/ParC, GyrB/ParE. Each pair of subunits is quite similar
leading to inhibition of the pair by many inhibitors hence dual tar-
geting. Quinolones target GyrA/ParC whereas coumarins target the
catalytic ATP binding site of the GyrB/ParE. Since these targets rep-
resent two different and independent mechanisms various screen-
ing approaches have been adopted, for example, ATPase based
enzyme and empirical whole cell assays followed by MOA determi-
nation. Several reports of virtual screening has been also reported.21
Screening of a small library by the Vertex group using an ATPase
assay led to the identiﬁcation of benzimidazole carbamate lead (2,
Staphylococcus aureus serum shifted MIC >16 lg/mL, S. aureus gyr-
ase Ki 2 lM, topo IV Ki >60 lM, Fig. 1), which was systematically
optimized using novobiocin bound Escherichia coli GyrB. Multiple
iterations of structure-based design led to an optimized benzimid-
azole urea lead VRT-752586 (3, S. aureus MIC 0.5 lg/mL, gyrase Ki
0.014 lM) with signiﬁcantly improved potency and Gram-positive
spectrum including ParE (topo IV Ki 0.023 lM) activity.22 Unfortu-
nately enzyme potency improvement did not result in activity
against critical Gram-negative pathogens due to permeability and
efﬂux. VRT-752586 showed in vivo efﬁcacy in murine thigh model
of S. aureus infection (dosed iv) and murine lung pneumonia model
of Streptococcus pneumoniae infection (dosed po) at less than
50 mg/kg.22 The dual targeting of 3 likely leads to low spontaneous
frequency of resistance of less than <1.3  1010 in S. aureus.23
Recently a thiazolopyridine (4) was reported as an optimized gyr-
ase B inhibitor (Mycobacterium smegmatis GyrB IC50 <0.5 nM and
Mtb MIC 0.5 lM).24
Tari et al. reported anovel tricyclic gyrase B inhibitor (6) basedon
a fragment screening hit (5) followed by structure-guided lead opti-
mization.25 This compound showed potent inhibition of Enterococ-cus faecalis GyrB and ParE each with IC50 <0.3 nM. It showed
potent antibacterial activity and spectrum including Klebsiella pneu-
moniae,Acinetobacter baumannii and Pseudomonas aeruginosa. Itwas
efﬁcacious in various murine models of infections at single doses of
5–15 mg/kg. The activity was bactericidal and showed low
(2  1011) spontaneous frequency of resistance.25
Likewise the AstraZeneca group used a fragment-based lead
generation approach incorporating known gyrase inhibitor frag-
ments, such as pyrrole, and NMR screening using the 24 kDa N-ter-
minal ATP binding domain of E. coli GyrB, and they identiﬁed a
pyrrolamide fragment 7.26 A structure-guided lead optimization
approach using the E. coli gyrase crystal structure led to identiﬁca-
tion of a potent (MIC sub to low lg/mL) and broad-spectrum
Gram-positive agent 8 with activity against selected Gram-
negative bacteria with in vivo efﬁcacy along with 150-fold
improvement of activity over compound 7. Compound 8 competes
with ATP for binding at the ATP binding site of the gyrase B sub-
unit. It is a bactericidal agent. It is not clear whether these com-
pounds are dual targeting, though the frequency of resistance is
low (<109). Cross-resistance to novobiocin was observed but not
to quinolones consistent with binding to ATP site.26
A series of non-ﬂuoroquinolone novel bacterial type II topoiso-
merase inhibitors (NBTIs) have been recently described.27 These
inhibitors bind to gyrase A and ParC subunits, at a site different
from the ﬂuoroquinolones (e.g., ciproﬂoxacin, 9, Fig. 2) and amino-
coumarin-binding site. They show no cross-resistance to ﬂuoro-
quinolones and aminocoumarins.28–38 The distinct-binding site of
these inhibitors was demonstrated by X-ray crystal structures of
several inhibitors (e.g., GSK299423,28 10, Fig. 2 and AM8191,
11)39 bound to gyrase-DNA complex of S. aureus. NBTIs comprise
three structural motifs: A left hand site (LHS) bicyclic aromatic het-
erocycle, a right hand side (RHS) aromatic heterocycle connected
by a 8-atom central linker contacting a basic nitrogen at posi-
tion-7. The X-ray crystal structure exhibited a salt-bridge interac-
tion between the basic nitrogen atom at position-7 and the
Asp83.28,39 A wide-range of linkers are tolerated as long as linker
length and position of the basic nitrogen is maintained. These com-
pounds generally impart potent and broad-spectrum activity
including Gram-negative activity but suffer from hERG activity.
The hERG activity is highly dependent on overall polarity, which
negatively correlates with the Gram-negative activity. For exam-
ple, addition of a hydroxy group in NBTIs improves hERG signal
with concomitant loss of activity against P. aeruginosa.39 These
compounds were originally discovered in 1999 by whole cell
screening.40 After lead optimization several of the NBTIs (e.g.,
NXL101, 12, Fig. 2) entered clinical development but were discon-
tinued due to hERG binding and associated Qtc prolongation.31
Recently GSK2140944 (13, S. aureus MIC90 0.5 lg/mL, S. pneumo-
niaeMIC90 0.25 lg/mL) entered into clinical development with sig-
niﬁcantly reduced hERG activity (IC50 1.4 mM).41 However it has
only weak Gram-positive spectrum. Representative examples of
NBTIs from AstraZeneca (14, hERG IC50 233 lM)38 and actelion
(15, hERG IC50 19% hERG block at 10 lM) are presented in
Figure 2.42 It appears less likely for this lead series to deliver a
broad-spectrum agent due to negative correlation of hERG and
Gram-negative activity.
Barbiturate analog QPT-1 (PNU286607, 16, Fig. 2) was discov-
ered by empirical whole cell screening at Pharmacia Upjohn and
was subsequently determined as an inhibitor of DNA gyrase by
reverse genomics.43 It showed broad-spectrum Gram-positive anti-
bacterial activity with coverage of Haemophilus inﬂuenzae and
in vivo efﬁcacy. It shows no cross-resistance to quinolones and
novobiocin. It targets the b-subunit of bacterial topoisomerase II
but the binding site is likely different from quinolones and couma-
rins due to lack of cross-resistance. Lead optimization of this class
of compounds at AstraZeneca led to the identiﬁcation of isoxazole
Figure 1. Chemical structures of gyrase B/ParE inhibitors interacting at ATP binding site.
Figure 2. Chemical structures of gyrase A/ParC inhibitiors.
3686 S. B. Singh / Bioorg. Med. Chem. Lett. 24 (2014) 3683–3689analog AZD0914 (17).44 This compound showed Gram-positive
spectrum along with activity against fastidious Gram-negative
bacteria, and anaerobes45 including Neisseria gonorrhoeae46 with
low resistance potential.47 AZD0914 entered in phase I clinical
development in 2013.The gyrase inhibitors reported in Figure 2 are representative
examples selected from a large structural variety27 including 2-
pyridines and isothiazolopyridones (18),48 quinolones and isot-
hiazoloquinolones (19),49–51 aminoquinazolinediones (20),52
piperidyl-pyrazoles (21),53 4,50-bisthiazole (22),54 and natural
S. B. Singh / Bioorg. Med. Chem. Lett. 24 (2014) 3683–3689 3687products quercetin glycosides,55 kibdelomycin.13 These inhibitors
bind to different part of the gyrase enzyme eliciting inhibitory
response akin to mammalian receptors.
Tetracycline derivatives. With the development of the new con-
vergent total synthesis of the tetracycline class of compounds,4,5
the group at Tetraphase synthesized eravacycline (23, Fig. 3) a
new C-7 ﬂuoro analog of 70 year-old natural product tetracycline
by total synthesis. The compound overcame common tetracy-
cline-speciﬁc efﬂux and ribosomal protection mechanisms and
therefore show no cross-resistance with tetracycline and main-
tains broad-spectrum activity.56 Eravacycline entered phase 3 clin-
ical trials for complicated urinary tract infections (cIUI) and
complicated intra-abdominal infections (cIAI).56
Hybrid antibiotics. In order to modify the mechanism of action of
existing classes of antibiotics, efforts have been expended to make
chimeric antibiotics in which two mechanically distinct antibacte-
rial classes are covalently attached to produce a new hybrid antibi-
otic. Cadazolid (24), a ﬂuoroquinolone-oxazolidinone hybrid,
represents a prototypical example.6 It entered in phase II clinical
development for Clostridium difﬁcile infection with a proﬁle supe-
rior to vancomycin.6 Similar chimeric approaches have been taken
with other classes (e.g., quinolizine-rifamycin57 quinolone-DHFR,58
quinolone-aminoglycoside59). Unfortunately, the challenge inher-
ent to this approach is increased MWwhich will affect oral absorp-
tion, if oral treatment are needed. The group at Actelion took
advantage of this inherent ﬂaw for the development of cadazolid
for CDAD indication.
b-Lactamase inhibitors. Inhibition of b-lactamase to restore
Gram-negative activities of b-lactam antibiotics continue to play
substantial role in combating resistance caused by expression of
a variety of b-lactamases. Avibactam (25, Fig. 3) and MK-7655
(26), two members of a novel bridged diazabicyclo[3.2.1]octanone
class, are in advanced stages of clinical development. Avibactam
and MK7655 are potent inhibitors of class A, C and ESBL
b-lactamases and are partnered with ceftazidime and imipenem,
respectively, for restoring the activity against organisms producing
those b-lactamases.60 However, they do not provide coverage of
MRSA and metallo b-lactamases. RPX7009 (27) is a new class of
boronic acid based b-lactamase inhibitor with potent activity
(IC50 9–11 nM) and is in early stages of clinical development in
combination with biapenem.60
Efﬂux pump inhibitors. Like b-lactamase inhibition, inhibition of
efﬂux pumps is another strategy, which merits attention. Various
efﬂux pump inhibitors have been reported including reserpine that
inhibits NorA efﬂux pump and improves MIC values of a number of
ﬂuoroquinolones.61 Many efﬂux pump inhibitors have been
reported62,63 including boronic acids64 that synergizes antibiotics
in vitro but none have advanced to clinical validation. WhileOH
O
NH2
OHOOOH
F
H H
HO
N
H
O
N
N
Eravacycline (23)
O
HO
N
O
H2N
N
O OSO3H
Avibactam (25)
N
O
N
H
N
O
MK7655
HN
Figure 3. Chemical structures of new tetracycline,development of b-lactamase inhibitors has been proven, signiﬁcant
development challenges remain for the efﬂux pump inhibitors.1,62
Entry promoters. In order to improve entry in Pseudomonas a few
groups have taken advantage of its iron uptakemechanism,which is
essential for bacterial survival and growth. The iron uptake takes
place by binding to siderophores. The groups at Baselia and Pﬁzer
have successfully conjugated a hydroxypyridone siderophore moi-
ety to Gram-negative monobactams to produce BAL30072 (28,
Fig. 4)65 andMC-1 (29), respectively.66 These conjugates hijack bac-
terial siderophore transport system and trick the cells into import-
ing the active drug as if it was nutritionally beneﬁcial compound
and thus showed better permeability in P. aeruginosa. As a result,
these compounds showed signiﬁcantly improved in vitro activity
compared to non-siderophore containing parents. Although sidero-
phore strategy forMC-1demonstrated reasonable in vitro resistance
frequencies, these did not correlate in vivo and have raised concerns
about this as a viable approach. In addition, howthismechanismwill
work in the clinical setting where variable levels of iron and indige-
nous siderophores,with different iron afﬁnity, are present is unclear
and could be answered only from the clinical studies of one of these
compounds?67 While development status of MC-1 is unknown,
BAL30072 is in clinical development in part funded by BARDA.
LpxC inhibitors. Signiﬁcant efforts has been expended on the dis-
covery and development of inhibitors of LpxC, an essential enzyme
for the synthesis of lipid A in Gram-negative bacteria particularly
after the discovery of hydroxymic acid inhibitor L-161240 (30).
These efforts led to the discovery of potent inhibitors of LpxC
including CHIR-090 with potent (sub lg/mL) MIC against E. coli
and P. aeruginosa.1,68 While many hydroxymic acid based inhibi-
tors with potent LpxC activity have shown potent cellular activity
(perhaps entry is helped by metal transporters) many potent non-
hydroxymic acid LpxC inhibitors (e.g., hydantoins, phosphonic
acids) do not show cellular activity.68 ACHN-975 entered clinical
development but was halted due to injection site problems and
thus clinical outcome of LpxC inhibitors remains unclear.69
Antibiotic discovery is predominantly a molecule centric
approach3 and currently suffering from discovery of new lead/tar-
get pairs. Relatively straightforward processes exist for the target
identiﬁcation of a cell active antibacterial lead as has been per-
formed throughout the history of antibiotic discovery. Therefore,
it is paramount to focus on transforming the chemical diversity
with special emphasis on antibiotic-like physicochemical proper-
ties for the discovery of novel antibacterial leads. Natural products
have been major sources of antibacterial drugs. They have been
endowed with better entry (often using active transports),16
binding properties with soluble enzymes of intracellular targets.70
Natural products have been deemphasized for the last couple of
decades due to many real or perceived challenges, which couldN
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Figure 4. Chemical structures of siderophores and LpxC inhibitors.
3688 S. B. Singh / Bioorg. Med. Chem. Lett. 24 (2014) 3683–3689be rapidly addressed today with highly sensitive analytical tech-
nologies (dereplication), genome sequencing (awakening silent
cryptic biosynthetic pathways and predictive chemistry) and com-
binatorial biosynthesis and synthetic biology (complex structure
modiﬁcation, new structure generation). Signiﬁcant advances have
been also made in the development of target/pathway based phe-
notypic screens, which must be employed for screening regardless
of sources of compounds.71,72 Unfortunately, without improve-
ment of the quality of compounds for screening other improve-
ments including great phenotypic screens will not improve the
odds of success for the discovery of novel antibacterial agents with
novel mode of action. In order to improve the odds and reduce cost,
it might be an opportune time for discussion of development of a
consortium approach for design and synthesis of antibiotic speciﬁc
libraries. Various models could be envisaged for this approach such
as sharing of libraries and pairing that with proprietary assays. If
we continue with current trajectory of failed attempts, the conse-
quences could be dire, particularly if infected by resistant untreat-
able Gram-negative pathogens. We cannot return to pre-penicillin
days. Fortunately, initiatives such as IMI’s new drugs for bad bugs
(www.translocations.eu) and public discussions73 have started to
catalyze antibiotic discovery and incentivize the antibiotic discov-
ery and development. This would in turn help in improved return
on investment leading to increased investment by for-proﬁt
organizations.
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